

Korea DPR Support for Inactivated Polio Vaccine (IPV)

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Korea DPR				
2. Grant Number: 1518-PRK-25b-X / 1518-PRK-25c-X / 15-PRK-08h-Y				
3. Date of Decision Letter: 4 March 2015 (replaces the previous Decision Letter for IPV issued on 30 July 2014)				
4. Date of the Partnership Framework Agreement: 07 June 2013				
5. Programme Title: NVS, IPV Routine				
6. Vaccine type: Inactivated Polio Vaccine (IPV)				
7. Requested product presentation and formulation of vaccine¹: Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID				
8. Programme Duration²: 2015 - 2018				
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement): <i>Please note that endorsed or approved amounts for 2018 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes.</i>				
	2015	2016	2017	Total ³
Programme Budget (US\$)	US\$928,130	US\$869,500	US\$706,000	US\$2,503,630
10. Vaccine Introduction Grant: US\$289,000 ⁴ .				
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement).⁵				
Type of supplies to be purchased with Gavi funds in each year	2015	2016		
Number of IPV vaccines doses	450,700	424,700		
Number of AD syringes	420,400	355,700		
Number of re-constitution syringes				
Number of safety boxes	4,625	3,925		
Annual Amounts (US\$)	US\$928,130	US\$869,500		
12. Procurement agency: UNICEF				
13. Self-procurement: Not applicable				

¹ Please refer to section 18 for additional information on IPV presentation.

² This is the entire duration of the programme.

³ This is the total amount endorsed by Gavi for 2015 to 2017.

⁴ This amount refers to the Vaccine Introduction Grant under the existing Decision Letter dated 30 July 2014.

This amount is in the process of being disbursed and no further funding has been approved.

⁵ This is the amount that Gavi has approved.

14. Co-financing obligations: Not applicable

Gavi's usual co-financing requirements do not apply to IPV. However, Korea DPR is encouraged to contribute to vaccine and/or supply costs for IPV.

15. Operational support for campaigns: Not applicable

16. The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts:

Reports, documents and other deliverables	Due dates
Annual Progress Report or equivalent	To be agreed with Gavi Secretariat

17. Financial Clarifications: The Country shall provide the following clarifications to Gavi*:
Not applicable

18. Other conditions: Not applicable.

If Korea DPR envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Korea DPR.

Signed by,
On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes
4 March 2015